Home › Compare › SZLSF vs EQR

SZLSF vs EQR: Dividend Comparison 2026

SZLSF yields 39215.69% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SZLSF wins by $4.252735580217355e+22M in total portfolio value
10 years
SZLSF
SZLSF
● Live price
39215.69%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.252735580217355e+22M
Annual income
$42,315,093,309,418,040,000,000,000,000.00
Full SZLSF calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — SZLSF vs EQR

📍 SZLSF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSZLSFEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SZLSF + EQR cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
SZLSF pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SZLSF
Annual income on $10K today (after 15% tax)
$3,333,333.33/yr
After 10yr DRIP, annual income (after tax)
$35,967,829,313,005,333,000,000,000,000.00/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, SZLSF beats the other by $35,967,829,313,005,333,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SZLSF + EQR for your $10,000?

SZLSF: 50%EQR: 50%
100% EQR50/50100% SZLSF
Portfolio after 10yr
$2.1263677901086776e+22M
Annual income
$21,157,546,654,709,020,000,000,000,000.00/yr
Blended yield
99.50%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

SZLSF
No analyst data
Altman Z
-336.3
Piotroski
2/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SZLSF buys
0
EQR buys
0
No recent congressional trades found for SZLSF or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSZLSFEQR
Forward yield39215.69% ✓5.87%
Annual dividend / share$2.00$3.47 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8% ✓
Portfolio after 10y$4.252735580217355e+22M$47.8K ✓
Annual income after 10y$42,315,093,309,418,040,000,000,000,000.00 ✓$5,475.61
Total dividends collected$4.251340866571809e+22M$23.0K ✓
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: SZLSF vs EQR ($10,000, DRIP)

YearSZLSF PortfolioSZLSF Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$3,932,269$3,921,568.63$11,380$679.82+$3.92M → SZLSF
2$1,445,390,825$1,441,183,297.58$13,014$837.25+$1445.38M → SZLSF
3$496,629,048,205$495,082,480,022.34$14,961$1,036.20+$496629.03M → SZLSF
4$159,510,701,964,776$158,979,308,883,196.16$17,297$1,289.22+$159510701.95M → SZLSF
5$47,892,225,784,148,210$47,721,549,333,045,900.00$20,121$1,613.15+$47892225784.13M → SZLSF
6$13,442,027,069,357,296,000$13,390,782,387,768,257,000.00$23,561$2,030.84+$13442027069357.27M → SZLSF
7$3,526,928,149,355,307,700,000$3,512,545,180,391,095,400,000.00$27,783$2,573.54+$3526928149355307.50M → SZLSF
8$865,104,634,553,737,800,000,000$861,330,821,433,927,700,000,000.00$33,013$3,284.39+$865104634553737856.00M → SZLSF
9$198,376,161,453,751,100,000,000,000$197,450,499,494,778,630,000,000,000.00$39,547$4,223.51+$198376161453751107584.00M → SZLSF
10$42,527,355,802,173,560,000,000,000,000$42,315,093,309,418,040,000,000,000,000.00$47,791$5,475.61+$4.252735580217355e+22M → SZLSF

SZLSF vs EQR: Complete Analysis 2026

SZLSF — Stock

StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in the United States and Canada. Its proprietary platform technology is Sentinel Principle, which identifies novel biomarkers from whole blood. The company's lead product is Aristotle, a multi-cancer panel test for simultaneously screening for various cancers from a single sample of blood with high sensitivity and specificity for each cancer. It also offers ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer; COVID polymerase chain reaction testing and blood test analysis; Prostate Health Index, a screening test for prostate cancer; and BreastSentry, a test to determine a woman's risk for developing breast cancer. The company was founded in 1998 and is headquartered in Richmond Hill, Canada.

Full SZLSF Calculator →

EQR — REIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this SZLSF vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SZLSF vs SCHDSZLSF vs JEPISZLSF vs OSZLSF vs KOSZLSF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.